196 related articles for article (PubMed ID: 10233949)
1. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
White WI; Wilson SD; Palmer-Hill FJ; Woods RM; Ghim SJ; Hewitt LA; Goldman DM; Burke SJ; Jenson AB; Koenig S; Suzich JA
J Virol; 1999 Jun; 73(6):4882-9. PubMed ID: 10233949
[TBL] [Abstract][Full Text] [Related]
2. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
[TBL] [Abstract][Full Text] [Related]
3. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
4. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
5. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
Xu Y; Wang Q; Han Y; Song G; Xu X
J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
Roden RB; Armstrong A; Haderer P; Christensen ND; Hubbert NL; Lowy DR; Schiller JT; Kirnbauer R
J Virol; 1997 Aug; 71(8):6247-52. PubMed ID: 9223527
[TBL] [Abstract][Full Text] [Related]
7. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
[TBL] [Abstract][Full Text] [Related]
8. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.
Carter JJ; Wipf GC; Benki SF; Christensen ND; Galloway DA
J Virol; 2003 Nov; 77(21):11625-32. PubMed ID: 14557648
[TBL] [Abstract][Full Text] [Related]
9. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
[TBL] [Abstract][Full Text] [Related]
10. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
[TBL] [Abstract][Full Text] [Related]
12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
13. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.
Kim HJ; Lim SJ; Kwag HL; Kim HJ
PLoS One; 2012; 7(4):e35893. PubMed ID: 22563414
[TBL] [Abstract][Full Text] [Related]
14. Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.
Senger T; Becker MR; Schädlich L; Waterboer T; Gissmann L
J Virol; 2009 Dec; 83(24):12692-701. PubMed ID: 19793806
[TBL] [Abstract][Full Text] [Related]
15. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
16. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
[TBL] [Abstract][Full Text] [Related]
17. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P
Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703
[TBL] [Abstract][Full Text] [Related]
18. A deletion and point mutation study of the human papillomavirus type 16 major capsid gene.
Varsani A; Williamson AL; Jaffer MA; Rybicki EP
Virus Res; 2006 Dec; 122(1-2):154-63. PubMed ID: 16938363
[TBL] [Abstract][Full Text] [Related]
19. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.
Xia L; Xian Y; Wang D; Chen Y; Huang X; Bi X; Yu H; Fu Z; Liu X; Li S; An Z; Luo W; Zhao Q; Xia N
Sci Rep; 2016 Jan; 6():19042. PubMed ID: 26750243
[TBL] [Abstract][Full Text] [Related]
20. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
